New triple-drug combo aims to stall advanced breast cancer
NCT ID NCT07610720
First seen May 30, 2026 · Last updated Jun 10, 2026 · Updated 3 times
Summary
This study tests whether adding the drug dalpiciclib to standard anti-HER2 and hormone therapy can delay cancer progression in people with a certain type of advanced breast cancer (HR-positive, HER2-positive). About 57 adults whose cancer has not worsened after initial treatment will receive the combination as maintenance therapy. The goal is to see if this approach extends the time before the cancer starts growing again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-Sen University Cancer Center, Guangzhou, Yuexiu District
RECRUITINGGuangdong, GUANGZHOU, 510060, China
Conditions
Explore the condition pages connected to this study.